Abeona shareholders elect directors, approve 2023 equity plan at annual meeting

ABEONA THERAPEUTICS INC.

Michael Amoroso (6.5M for) and Christine Silverstein (6.2M for) elected Class I directors until 2026.
Abeona Therapeutics 2023 Equity Incentive Plan approved: 6.2M for, 569K against, 18K abstentions.
Advisory vote on named executive officer compensation passed: 6.4M for, 282K against, 37K abstentions.
Ratification of Whitley Penn LLP as independent auditor for FY2023 passed: 10.4M for, 49K against, 28K abstentions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.